Familial Breast Cancer Registry Program in Patients Referred to the Cancer Institute of Iran

  • Sabokbar, Tayebeh (Department of Genetics, Cancer Research Center, Cancer Institute of Iran) ;
  • Khajeh, Elias (Students Scientific Research Center & Exceptional Talent Development Center (ETDC), Tehran University of Medical Sciences (TUMS)) ;
  • Taghdiri, Foad (Students Scientific Research Center & Exceptional Talent Development Center (ETDC), Tehran University of Medical Sciences (TUMS)) ;
  • Peyghambari, Vahideh (Department of Genetics, Cancer Research Center, Cancer Institute of Iran) ;
  • Shirkoohi, Reza (Department of Genetics, Cancer Research Center, Cancer Institute of Iran)
  • Published : 2012.06.30


Introduction: Annually a considerable number of people die because of breast cancer, a common disease among women also in Iran. Identifying risk factors and susceptible people can lead to prevention or at least early diagnosis. Among susceptibility risks, 5-10% of patients have a family history predisposing factor which can influence the risk of incidence among the family. Having a registry program can be a more practical way to screen high risk families for preventive planning. Method: Based on inclusion criteria, a questionnaire was prepared and after a pilot study on a small number of patients, actual data were collected on 400 patients and processed in SPSS 16.0. Results: Totally, 28.2%of the patients were younger than 40 years old and 36.8% had the included criteria for familial breast cancer (FBC). 102 patient's samples could be compared for receptor presentation. Similar to other studies, the number of triple negative breast cancers increased as the age decreased. Conclusion: The high percentage of patients with FBC among 400 cases in this study demonstrates that in order to design an infrastructural diagnostic protocol and screening of patients with FBC, a precise survey related to frequency and founder mutations of FBC is needed nationwide.


  1. American Cancer Society. Cancer Facts and Figures 2012. Atlanta, Ga: American Cancer Society, 2012.
  2. Anand P, Kunnumakara A, Sundaram C, et al (2008). Cancer is a preventable disease that requires major lifestyle changes. Pharm Res, 25, 19.
  3. Bouwman P, Aly A, Escandell J, et al (2010 ). 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol, 17, 7.
  4. Carey L, Perou C, Livasy C, et al (2006). Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA, 295, 10.
  5. Carmichael AR, Harbach L, Cooke, R (2009). Breast clinic and life style study BLLISS. Int Semin Surg Oncol, 6, 12.
  6. Dobi Á, Kelemen G, Kaizer L, et al (2011). Breast cancer under 40 years of age: increasing number and worse prognosis. Pathol Oncol Res, 17, 3.
  7. Eberl MM, Sunga A, Farrel CD, et al (2005). Patients with a family history of cancer: identification and management. JABFP, 18, 211-8.
  8. Eccles DM, Evans DGR, Mackay J, et al (2000). Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J Med Genet, 37, 203-9.
  9. Fostira F, Tsitlaidou M, Papadimitriou C, et al (2012 ). Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat, 134, 353-62.
  10. Ghaderi A, Talei A, Farjadian S, Mosalaei A, Doroudchi M, Kimura H (2001). Germline BRCA1 mutations in Iranian women with breast cancer. Cancer Lett, 165, 87-94.
  11. Ghaderi A, Talei A, Gharesi-Fard B, et al ( 2001). 24HLA-DBR 1 alleles and the susceptibility of Iranian patients with breast cancer. Pathol Oncol Res, 7, 39-41.
  12. Goldgar DE (2002). Population aspects of cancer genetics. Biochimie, 84, 19-25.
  13. Hajian-Tilaki K, Kaveh-Ahangar T, Hajian-Tilaki E (2011). Is educational level associated with breast cancer risk in Iranian women? Breast Cancer, 19, 64-70.
  14. Hannemann J, Kristel P, van Tinteren H, et al (2006). Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Br J Cancer, 95, 7.
  15. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A (2000). Breast cancer in Iran: a review of 903 case records. Public Health, 114, 143-5.
  16. Harirchi I, Karbakhsh M, Kashefi A, Momtahen AJ ( 2004). Breast cancer in Iran: results of a multi-center study. Asian Pac J Cancer Prev, 5, 24-7.
  17. Hussain SK, Altieri A, Sundquist J, Hemminki K (2008). Influence of education level on breast cancer risk and survival in Sweden between 1990 and 2004. Int J Cancer, 122, 165-9.
  18. Jonker M, Jacobi CE, Hoogendoorn WE, et al (2003). Modeling familial clustered breast cancer using published data. Leiden Univ Med Univ, 12, 1479-85.
  19. Katki HA (2006). Effect of misreported family history on Mendelian mutation prediction models. Biometrics, 62, 478-87.
  20. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A(2007). Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet, 173, 38-42.
  21. Lee, E. (2008). Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones. Curr Opin Obstet Gynecol, 20, 5.
  22. Lund M, Butler E, Hair B, et al (2010). Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report. Cancer, 116, 10.
  23. Minceym BA (2003). Genetics and the Management of Women at high risk for breast cancer. The Oncologist, 8, 466-73.
  24. Monge AR, Espeleta GAG, Vega KL (2004). Familial Breast Cancer in Costa Rica:An initial approach. Revista de Biologia Tropical, 52, 531-6.
  25. Moslehi R, Kariminejad MH, Ghafari V, Narod S (2003). Analysis of BRCA1 and BRCA2 mutations in an Iranian family with hereditary breast and ovarian cancer syndrome. Am J Med Genet A, 117A, 304-5.
  26. Mousavi SM, Mohaghegghi MA, Mousavi-Jerrahi A, Nahvijou A, Seddighi Z (2006). Burden of breast cancer in Iran: a study of the Tehran population based cancer registry. Asian Pac J Cancer Prev, 7, 571-4.
  27. Nordin K, Roshanai A, Bjorvatn C, et al ( 2011). Is genetic counseling a stressful event? Acta Oncol, 50, 1089-97.
  28. Ohadi M, Totonchi M, Maguire P, et al ( 2007). Mutation analysis of the DBC2 gene in sporadic and familial breast cancer. Acta Oncol, 46, 770-2.
  29. Peto J, Collins N, Barfoot R, et al (1999). Prevelance of BRCA1/2 mutations in patients with early onset breast cancer. J Natl Cancer Inst, 91, 943-9.
  30. Pietschmann A, Mehdipour P, Mehdipour P, et al (2005). 22Mutation analysis of BRCA1 and BRCA2 genes in Iranian high risk breast cancer families. J Cancer Res Clin Oncol, 131, 552-8.
  31. Ropka ME, Wenzel J, Phillips EK, et al (2006). Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomarkers Prev, 15, 840-55.
  32. Salami S, Ramezani F, Aghazadeh T, et al (2011). Impact of triple negative phenotype on prognosis and early onset of breast cancer in Iranian females. Asian Pac J Cancer Prev, 12, 5.
  33. Seal S, Barfoot R, Jayatilake H, et al (2003). Evaluation of fanconi anemia genes in familial breast cancer predisposition. Cancer Res, 63, 8596-9.
  34. Slijepcevic P (2007). Familial breast cancer: recent advances. Brunel Institute of Cancer Genetics and Pharmacogenomics, Division of Biosciences, School of Health Sciences and Social Care, Brunel University, 38-43.
  35. Stewart BW (2001). Familial Breast Cancer (information for GPs),. south Eastern Sydney Area Health Service. Cancer control Bulletin, 19.
  36. The Ministry of Health Treatment and Medical Education. (1385). Cancer Registration National Report in 1383. Center for Disease Control, 313.
  37. Vogel JE, Chu C, McCullough M, et al (2011). Breast cancer in women under age 40 years: treatment by total mastectomy and reconstruction. Ann Plast Surg, 66, 557-60.
  38. Warner E, Heisey RE, Goel V, Carroll JC, McCready DR (1999). Hereditary breast cancer. Risk assessment of patients with a family history of breast cancer. Can Fam Physician, 45, 104-12.
  39. World Cancer Report (2011). Breast cancer: prevention and control. International Agency for Research on Cancer. Retrieved-02-26. World Health Organization.
  40. Yassaee VR, Zeinali S, Harirchi I, et al (2002). 23Novel mutations in the BRCA1 and BRCA2 genes in Iranian women with early-onset breast cancer. Breast Cancer Res, 4, R6.
  41. Yeo W, Kwan WH, Lee WY, Leung TWT, Teo PML (1996). Familial breast cancer in Hong Kong Chinese. HKMJ, 2, 68-71.
  42. Young S, Pilarski R, Donenberg T, et al (2009). The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer, 9, 86

Cited by

  1. Identification of Germline BRCA1 Mutations among Breast Cancer Families in Northeastern Iran vol.14, pp.7, 2013,
  2. Overview of Cancer Registration Research in the Asian Pacific from 2008-2013 vol.14, pp.8, 2013,
  3. A Registry Program for Familial Gastric Cancer Patients Referred to Cancer Institute of Iran vol.15, pp.5, 2014,
  4. Risk of Breast Cancer in Relation to Reproductive Factors in North-west of Iran, 2013-2014 vol.16, pp.2, 2015,